Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Trial of NK105 vs Paclitaxel in Advanced or Recurrent Breast Cancer
jRCT2080223812Phase 2Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Feb 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of NK105 in breast cancer (2 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoints: Efficacy comparison between NK105 and paclitaxel and Safety and tolerability of weekly NK105. Started Feb 2018; status: completed.
02
Drugs
NK105
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223812.